These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
933 related articles for article (PubMed ID: 22946753)
1. Vemurafenib: in unresectable or metastatic melanoma. Keating GM BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753 [TBL] [Abstract][Full Text] [Related]
2. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
7. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
9. Vemurafenib. Value unclear in metastatic melanoma. Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092 [TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639 [TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial. Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686 [TBL] [Abstract][Full Text] [Related]
12. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. Seeley AR; De Los Santos JF; Conry RM Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037 [TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Del Vecchio M; Ascierto PA; Mandalà M; Sileni VC; Maio M; Di Guardo L; Simeone E; Queirolo P Future Oncol; 2015; 11(9):1355-62. PubMed ID: 25952781 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Sinha R; Larkin J; Gore M; Fearfield L Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403 [TBL] [Abstract][Full Text] [Related]
15. Safety of vemurafenib in patients with BRAF Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408 [TBL] [Abstract][Full Text] [Related]
16. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations. Yamazaki N; Kiyohara Y; Sugaya N; Uhara H J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515 [TBL] [Abstract][Full Text] [Related]
18. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA; N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808 [TBL] [Abstract][Full Text] [Related]
19. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]